Bright Green Partners with Benuvia Pharmaceuticals
Bright Green Corporation (NASDAQ: BGXX) has announced that it has entered into a letter of intent to provide its DEA-approved marijuana extracts and plant-based psychedelics to Benuvia Operations. Benuvia is recognized as a leader in the field of pharmaceutical cannabinoids and is currently exploring the clinical use of psychedelic molecules.
Strategic Supply Agreement
This agreement underscores Bright Green’s dedication to supplying high-quality organic materials to pharmaceutical partners in the U.S. Benuvia plans to utilize Bright Green’s unique capabilities to produce Schedule I & II raw materials while adhering to Good Agricultural and Collection Practices (GACP), Good Manufacturing Practices (GMP), and DEA regulations, all within the United States.
Advancing Pharmaceutical Development
Bright Green aims to establish itself as the premier domestic supplier of DEA-controlled, plant-based raw materials for cannabinoid, psychedelic, and opioid-based medications. With ongoing fundraising efforts and supply agreements, Bright Green is strategically positioned for robust growth and success.
Compliance and Standards
The Drug Enforcement Administration (DEA) has finalized its annual operational procedures for the cultivation and manufacturing of Schedule I & II drugs. Bright Green adheres to these stringent national standards and is nearing the start of operations to provide essential materials to the pharmaceutical sector.
About Bright Green Corporation
Bright Green is among the select few companies authorized to legally cultivate, manufacture, and sell Schedule I and II plant-based drugs under both federal and state law. With its DEA approval, Bright Green is advancing its mission to enhance quality of life through cannabis and other plant-derived therapies.
About Benuvia
Benuvia Operations, LLC is a frontrunner in the research, development, and commercialization of innovative pharmaceutical products. With a strong commitment to improving patient outcomes through scientific research and quality practices, Benuvia is at the cutting edge of the pharmaceutical industry.
Media Inquiries & Investor Relations
For media inquiries and investor relations, please reach out to ir@brightgreen.us.
Frequently Asked Questions
What is the nature of the partnership between Bright Green and Benuvia?
The partnership entails Bright Green supplying DEA-approved marijuana extracts and plant-based psychedelics to Benuvia for use in pharmaceuticals.
What are the regulatory approvals held by Bright Green?
Bright Green is authorized by the US government and the New Mexico Board of Pharmacy to legally cultivate, manufacture, and sell Schedule I and II plant-based drugs.
What standards does Bright Green comply with?
Bright Green adheres to Good Agricultural and Collection Practices (GACP) and Good Manufacturing Practices (GMP).
What is Benuvia known for?
Benuvia is well-known for its FDA-approved medication SYNDROS, which is used to treat anorexia associated with weight loss in AIDS patients and to manage nausea and vomiting induced by chemotherapy.
How does this partnership affect the pharmaceutical market?
This partnership is anticipated to improve the availability of high-quality raw materials in the pharmaceutical market, particularly for cannabinoid and psychedelic products.
